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Rac GTPases in human diseases
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Abstract. Rho GTPases are members of the Ras superfamily of GTPases that regulate a wide variety of cellular functions. While
Rho GTPase pathways have been implicated in various pathological conditions in humans, to date coding mutations in only
the hematopoietic speciﬁc GTPase, RAC2, have been found to cause a human disease, a severe phagocytic immunodeﬁciency
characterized by life-threatening infections in infancy. Interestingly, the phenotype was predicted by a mouse knock-out of Rac2
and resembles leukocyte adhesion deﬁciency (LAD). Here we review Rho GTPases with a speciﬁc focus on Rac GTPases. In
particular, we discuss a new understanding of the unique and overlapping roles of Rac2 in blood cells that has developed since
the generation of mice deﬁcient in Rac1, Rac2 and Rac3 proteins. We propose that Rac2 mutations leading to disease be termed
LAD type IV.
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1. Rho GTPases
The Rho family of GTPases are genes that en-
code small monomeric Ras-related proteins [9]. The
Rho proteins can be divided into 6 families based
on sequence homology, protein domains and function.
TheseincludeRac,RhoA,Cdc42,TC10andTCL,Rnd,
the Rho BTB subset and the Miro subfamily. There
are at least 18 members of the Rho GTPase family of
proteins. RhoA, Rac and Cdc42 are the best studied of
these proteins. Studies in ﬁbroblasts have providedthe
initial insights intothe cellularfunctionof Rho GTPas-
es in actin cytoskeletal reorganization [42]. As con-
ﬁrmed by studies in manyother mammaliancells, acti-
vationof RhoA, Rac1 and Cdc42induces the assembly
ofthree distinct ﬁlamentous(F)-actinstructuresrespec-
tively through separate signaling pathways [72]. In
contrast to RhoA, which induces actin stress ﬁber for-
mation,twoothermembersoftheRhosubfamily,RhoD
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and RhoE, stimulate the disassembly of stress ﬁbers
and thereby inhibit cell motility [31,78]. Therefore,
Rho GTPases appear to exert both positive and nega-
tive functional effects on regulating actin cytoskeleton
reorganizationand actin-based function in cells.
Rho GTPases have now been also recognized as in-
tracellular switches to transduce signals from a wide
variety of membrane receptors, including tyrosine ki-
nase receptors and integrins, and more recently the T
and B cell receptors [7,31,78,81]. They have been im-
plicated in regulating a variety of cellular functions in-
cluding cell proliferation, G1 cell cycle progression,
adhesion, motility and apoptosis [31,78], including in
hematopoietic cells (see below). Many studies have
demonstrated that the c-Jun N-terminal kinase (JNK)
and p38 MAP kinase pathways are activated by Rac
and Cdc42 [80]. RhoA, Rac and Cdc42 have each
been reported in different cell systems to regulate nu-
clear signaling through activation of serum response
factor and nuclear factor κB (NF-kB) [61]. In con-
trast to RhoA, Rac and Cdc42, RhoB appears to sup-
press the activation of NF-kB [32]. Therefore, RhoB,
in combination with RhoD and RhoE, represents a dis-
tinct group of Rho GTPases that have functional ef-
fects antagonistic to those of other Rho GTPases, such
as RhoA, Rac and Cdc42. Competition between these
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groups of Rho GTPases may provide another level for
regulating particular Rho GTPase-activated signaling
pathwaysrelatedto diseasedevelopment. Forinstance,
Hansen et al. have demonstrated the competition be-
tweenRhoAandRhoEinregulatingRas-inducedtrans-
formation of epithelial cells via the Raf-Mek-ERK ki-
nase pathways [43]. We and others have demonstrated
that RhoH, whichis a hematopoietic-speciﬁc,GTPase-
deﬁcientRhoGTPase, antagonizesRac inlymphoblas-
tic cell lines and primary myeloid progenitor cells [16,
54].
Similar to Ras proteins, Rho GTPases are subject to
posttranslational modiﬁcations, in which the proteins
are lipid modiﬁed by prenylation at a conserved cys-
teineinthecarboxy(C)-terminalCaaLsequence(where
C is cysteine, a is an aliphatic amino acid, and L is
leucine). Immediately adjacent to this CaaL sequence,
several members of the family also contain an impor-
tant ‘polybasic domain’, which has been shown in Ras
proteins to modify the strength of the membrane lo-
calization. Subsequent to prenylation, the C-terminal
tripeptide(aaL)is removedbyproteolysis, andthe new
C-terminal amino acid is methylated [27,33,34,73,89].
Lipid modiﬁcations of Rho GTPases are critical for
membrane association and for protein-protein interac-
tions [64]. As described below, both the ‘polybasic’
domain and the conserved CaaL sequence are particu-
larly important in determiningRac protein localization
and therefore function in blood cells.
In agreement with the wide variety of roles served
by Rho GTPases [45], deregulation of Rho GTPase-
related signaling pathways [for example the Cdc42
pathway and its effector Wiskott-Aldrich Syndrome
protein (WASp)] have been implicated in human dis-
eases. The abnormal activities of these proteins have
beenassociated with cellular transformationand tumor
progression, either by enhancing the metastasis of the
transformedcells or by serving as ancillary factors that
contribute to the transforming activity of oncoproteins
such as Ras [79,92]. However, unlike Ras, the only
GTPase found to have a mutated coding sequence in
human disease is the RAC2 gene. Additionally, muta-
tions in the ﬁrst intron of RHOH, a GTPase-deﬁcient
member of the Rnd family, have been implicated in
B cell malignancies (reviewed in [70]). Interestingly,
Rac2andRhoHaretheonlyRhoGTPaseswithexpres-
sion restricted to the hematopoietic cells. This review
will focus on Rho GTPases of the Rac family, and the
role of RAC2 speciﬁcally in human diseases.
2. Rac GTPases
SimilartoRas, Racproteinsactasmolecularswitch-
es that cycle between inactive, guanosine diphos-
phate(GDP)-boundandactive, guanosinetriphosphate
(GTP)-boundstates. GTP-bound(active)Rac interacts
with a variety of speciﬁc effectors or target molecules
to trigger diverse cellular responses. Activation of Rac
is typically induced by Dbl-family guanine nucleotide
exchangefactors (GEFs) that are activatedby receptor-
dependent kinases [91]. Acceleration of the intrinsic
GTPase function of the proteins by GTPase activating
proteins (GAPs) removes the γ-phosphate and returns
the active GTPase to a GDP-bound (inactive) form of
the protein. Additional regulationmay involve seques-
tering or stabilizing the inactive, GDP-bound protein
via GDP dissociation inhibitors (GDIs) within the cy-
toplasm. Almost all Rho family GTPases, including
Rac, stimulate actin polymerizationwithin the cell and
regulate changes in cytoskeletal structure that affect
cell shape, migration, and adhesion. These processes
are clearly important for immune cells, including lym-
phocytes and neutrophils, but are also critical for more
primitivehematopoieticstemandprogenitorcells. The
roleofRacGTPasesinthesemoreprimitivehematopoi-
etic cells has recently been reviewed [14,60] and will
not be covered here.
3. Role of Rac GTPases in immune cells
There are three isoforms of Rac proteins in mam-
mals, which areRac1, Rac2, and Rac3. Rac1 andRac2
share over 90% identity in primary sequence, and all
threeisoformsshareahighdegreeofaminoacididenti-
ty (∼89% overall). As noted above, expression of Rac
proteins differs substantially in tissue distribution and
levelsofexpression. Rac1andRac3proteinsarewidely
expressed in different tissues, whereas as noted above
Rac2 expression is restricted to cells of hematopoietic
origin.
The cellular functions that are the result of activa-
tion of Rac GTPases are determined in part by a multi-
tude of cellular effector proteins. These are likely both
agonist- and cell lineage-speciﬁc, although much re-
mains to be understood about Rho GTPases’ effectors
in primarycells. However,some downstreameffectors
of Rac have been implicated in primary hematopoietic
cells. Depending on the speciﬁc lineage and agonist,
Rac can activate p42/p44 and p38 MAPK, JNK, and
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ulate cell survival and proliferation via cell cycle pro-
gression. Wnt/β-catenin signaling has also been pro-
posed as a key signal in maintenance of hematopoietic
stem cell (HSC) quiescence [30,65,66]. For instance,
Wu et al. found that Rac1 complexes with JNK2 and
β-catenin [84]. In this complex, Rac1 acts through
JNK2 kinase to promote phosphorylation of β-catenin
at Ser191 and Ser605 residues, which in turn induces
nuclear translocation via the canonical Wnt-dependent
β-catenin activation pathway. Interestingly, Rac and
McgRacGAP also are required for nuclear localiza-
tion of Stat5a [49], suggesting that Rac proteins di-
rectly or indirectly regulate nuclear localization of fac-
tors involved in gene regulation. PAK, POR1, and
STAT5 have been implicated in Rac functions in pri-
mary hematopoietic cells, particularly in cytoskeletal
functions and transcription regulation. Many of these
studies in primary cells have been the result of the
availabilityofmouseknock-outlinesleadingtoamuch
more precise understanding of how Rac GTPases reg-
ulate cell behavior.
Because the sequences of all three mammalian Rac
proteins are quite similar, it is has been difﬁcult to un-
derstand how these related proteins regulate different
cell functions. Importantly Rac2 differs from Rac1
and Rac3 in the primary sequence located near the C-
terminal CaaL sequence, in a domain analogous the
Ras “hypervariable region”. This region in Rac1 (and
in K-Ras) is highly poly-basic in nature. We and oth-
ers have utilized gene-targeted mice to understand the
unique functions of each Rac protein in mammalian
cells. For instance, we have shown that in spite of the
overall sequence similarity between Rac1 and Rac2,
Rac2servesuniquefunctionsinhematopoieticcells re-
latedtointracellularlocalization,whichiscontrolledin
large part by the divergent sequences in the ‘polybasic
domain’ between Rac1 and Rac2 [28,76]. These dif-
ferences in Rac1 and Rac2 functions will be described
in more detail below.
4. In vitro studies
Much of the early knowledge of the roles of Rac
GTPases in hematopoietic cells were derived from in
vitro studies utilizing either constitutive active (CA) or
dominant negative (DN) mutants. Many of these stud-
ies were carried out in cell lines and focused on roles
in immunecells, speciﬁcally phagocyticcells and lym-
phocytes. In phagocytic cells, two critical and linked
functions have been studied: cell shape change asso-
ciated with adhesion and migration and the generation
of phagocytic oxidants required for killing bacteria. In
these studies, transient expression of mutant Rac cD-
NAs supported a role for Rac in membrane rufﬂing,
lamellipodiaformation,andmigrationofamacrophage
cell line [4,5,21]. Both Rac1 and Rac2 have been
knownforsometimetoberequiredincell-freesystems
to generate NADPH-dependent phagocytic oxidase [2,
52]. Interestingly, the difference in the C-terminal tail
of Rac has been shown to affect the efﬁciency of inter-
action with p67phox, one of the key proteins in the ox-
idase complex. Previous studies also have suggested a
role for Rac in lymphocyte development and function.
For instance, Rac2 mRNA increases 30- to 50-fold in
human T cells stimulated with hemagglutinin A [63],
and transgenicexpressionof constitutivelyactive Rac2
in the thymus leads to increased apoptosis and thymic
atrophy [55]. When the activities of both Rac1 and
Rac2 are inhibited by overexpression of a DN form of
Rac in T-cell lines, T-cell activation downstream of the
T-cell receptor, as well as the costimulatory molecules
CD28 and CD5, are substantially reduced [8,37,44].
In Jurkat cells, antisense inhibition of Rac2 results in
diminished actin polymerization triggered by ligation
of L-selectin [11]. Thus, prior to the development of
knock-outmice ofeachRac GTPase, therewas already
considerable evidence that Rac proteins played a criti-
cal role in various immune cells.
While previouswork using mutants of Rac (and oth-
er Rho GTPases) have contributed much to the under-
standing of the role of Rho GTPases in various cells,
these methods have limitations. For instance, the lev-
els of expressedproteinsare non-physiologicandwork
in cell lines may not accurately reﬂect primary cells.
In addition, constitutively active and dominantly neg-
ative mutants often have non-speciﬁc effects on mul-
tiple pathways due to abnormal binding of GEFs and
effectors. A signiﬁcantadvancein theﬁeld was the use
of gene-targeting in mice, which both allows analysis
of effects in primary cells and eliminates some of the
non-speciﬁceffectsofexpressingmutantproteins. The
ﬁrst reported use of mouse genetics to study Rho GT-
Pases was the knock-out of Rac2 [67], which showed
a phagocytic immunodeﬁciency that facilitated iden-
tiﬁcation of the ﬁrst patient with a GTPase mutation.
This study also demonstrated conclusively that Rac2
has functions unique from Rac1 (Table 1). Subsequent
reports of conditional knock-outs of Rac1 and knock-
out of Rac3, allowed a better understandingof both the
uniqueandoverlappingrolesoftheseGTPasesinblood
andothertissues [14]. For instance, geneticablation of180 S.-Y. Pai et al. / Rac GTPases in human diseases
Table 1
Summary of laboratory abnormalities described in patients and mice with Rac2 deﬁciency
Function tested Assay used Case 1 Case 2 Rac2−/− mouse
Hematologic Neutrophil count Increased Increased Increased
Hemoglobin Normal Reduced Normal∗
T cell count Low-normal Reduced Normal∗
TREC ? Reduced –
Exudate formation Reduced Reduced Reduced
Susceptibility to bacterial infection Increased Increased Normal
Susceptibility to fungal infection – – Increased
NADPH oxidase Response to PMA Normal Normal Reduced
Response to fMLP Absent Absent Reduced
Response to PMA and TNFα – – Normal
Response to serum-opsonized zymosan – – Normal
Response to IgG-SRBC – – Reduced
Response to Zymosan activated serum Reduced – –
Adhesion Expression of L-selectin – – Normal
Tethering to GlyCAM-1 Reduced – Reduced
Tethering to P-selectin – – Normal
Spreading on anti-integrin antibodies – – Reduced
Chemotaxis Response to fMLP Reduced – Reduced
Response to IL-8 – – Reduced
Response to LTB4 – – Reduced
Migration by Response to fMLP Reduced – Reduced
videomicroscopy
F-actin formation Response to zymosan activated serum Reduced Reduced ?
Response to fMLP Reduced Reduced Reduced
Response to IL-8 Reduced – Reduced
Response to TNF-α – – Normal
Response to GM-CSF – – Normal
Response to fMLP + TNF-α – – Normal
Response to fMLP + GM-CSF – – Normal
Phagocytosis FcR-mediated Reduced – Reduced
Degranulation Azurophilic granule release Absent – Reduced
Speciﬁc granule release Normal – Normal
References: [6, 7, 27, 53, 61, 79, 84, 87, unpublished data, C. Kim and M. Dinauer, manuscript submitted, J.
Verbsky and J. Routes].
∗These parameters are reduced in mice with deﬁciency of both Rac1 and Rac2.
Rac1 in the mouse embryonic limb bud ectoderm dis-
rupts canonical Wnt signaling and phenocopies dele-
tion of β-catenin in causing severe truncations of the
limb development [75,84].
5. Studies of Rac GTPases in neutrophils and
macrophages using gene targeted mice
Rac2−/− mice have a phenotype similar to the hu-
man diseases of leukocyte adhesion deﬁciency and
chronic granulomatous disease, including increased
susceptibility to Aspergillus infection [67]. The mice
show a prominent leukocytosis likely due to reduced
shear-dependentendothelial capture via L-selectin and
defectiveneutrophilchemotaxisinresponsetomultiple
agonists. Neutrophils have reduced F-actin assembly,
reduced phagocytosis and reduced superoxide produc-
tioninresponsetofMLP.Inactivatedneutrophils,Rac2
hasasubcellularmicrolocalizationdistinctfromthatof
Rac1, andabsence ofRac2 is associated with mislocal-
ization of Rac1 [28]. As mentioned above, the local-
izationofRac2isregulatedbyspeciﬁcsequencesinthe
‘polybasicdomain’oftheC-terminusandanadditional
uniqueresidueoutsidethisregionthathadnotprevious-
ly been associated with GTPase function. These two
distinctstructuraldeterminantsdeterminethespeciﬁci-
ty of Rac2 function in neutrophil chemotaxis and su-
peroxide generation, via Pak1, Por and p67phox, im-
plicating multiple, distinct and potentially parallel ef-
fector pathways [15]. Furthermore, Rac2 has distinct
functionsinneutrophils[35,51,54],andtheC-terminus
differences are critical to in vivo function of neu-
trophils[86]. Additionally,Rac2−/−macrophagesal-
so demonstrate selective defects in phagocytosis and
superoxide generation [85].
Neutrophils from mice simultaneously deﬁcient in
both Rac1 and Rac2 have a more pronounced migra-S.-Y. Pai et al. / Rac GTPases in human diseases 181
tion and adhesion defect compared with mice deﬁcient
in Rac2 [39], while neutrophils from mice deﬁcient in
onlyRac1 have nomigrationoroxidase productionde-
fect to fMLP, emphasizing both unique and overlap-
ping roles for Rac1 and Rac2. The more pronounced
phenotypeofmurineneutrophilsinthe absenceofboth
Rac1 and Rac2 may be relevant to the human disease
discussed later in this review, since over-expression of
a patient-derived DN mutant (D57N) suppresses both
Rac1andRac2activities[83]. Rac1andRac2mayalso
contributetoadifferentialresponsetoligandconcentra-
tions,andalsoshowdifferentkineticsofactivationafter
stimulationwithfMLPleadingtodistinct kineticsofF-
actinassemblyandcellshapechanges[90]. Degranula-
tionof primarygranulesin murineneutrophilsis Rac2-
dependent [1] and primary human neutrophil gran-
ule exocytosis is Rac-dependent [57]. Rac has been
demonstrated to mediate neutrophil and macrophage
responses that are critical to acute and chronic lung in-
jury in two murine models [24,29]. Rac2 appears to
have a modest effect on neutrophil development [36],
and in one study expression of a DN mutant also led
to myeloid cell dysplasia in vitro [76]. Overall, these
data generated from gene-targeted mice deﬁne critical
roles for both Rac1 and Rac2 in several aspects of neu-
trophil biology. Unanswered questions focus on which
upstream GEFs and downstream effectors are impor-
tant in neutrophil behavior related to Rac and to what
degree these other proteins regulate different functions
of Rac1 and Rac2 in these cells.
6. Rac2 in lymphocytes studied in gene targeted
mice
Croker et al. [22] has shown that Rac2 deﬁcien-
cy results in an abnormal T lymphocyte distribution
in vivo, which is associated with defects in both T-
lymphocyte migration and F-actin generation in re-
sponse to chemoattractants in vitro. The defects in
T cell distribution may be of relevance to the abnor-
malities in T cells reported in the second patient with
the D57N Rac2 mutation (see below). However, de-
spite the abnormalities in cytokine production and mi-
gration by T cells, Rac2-deﬁcient mice were not over-
ly sensitive to L. major infection, and cytotoxic T-
lymphocyte responses to cytomegalovirus and ovalbu-
min were also normal. Thus, Rac2 is required for nor-
mal T-lymphocyte migration, but its role in the gener-
ation of TH1 responses to infection in vivo appears to
be redundant.
Two groups generated double deﬁcient Rac1/Rac2
mice using a ﬂoxed allele of Rac1 crossed into
transgenic Cre and Rac2−/− mice(Rac1ﬂox/CD2-
Cre/Rac2−/−andRac1ﬂox/lck-Cre/Rac2−/−). These
mice show defects in thymocyte survival, beta selec-
tion and positive selection, that are moderate to severe,
depending on the strength of the deleting Cre trans-
gene [26,41]. Both models exhibit profound loss of
T cells in the periphery, which implies a post-thymic
survival or activation defect. Notably, deﬁciency of
Rac1 alone does not perturb T cell development. Guo
etal.[41]utilizedmiceconditionallydeletedofRac1in
eitherthe stem cell compartmentor the T cell compart-
ment,inthesettingofRac2deﬁciency. Theynotedthat
loss of both Rac1 and Rac2 in the stem cell compart-
ment leads to signiﬁcant deﬁciency of common lym-
phoidprogenitors,whereas loss of Rac1 onlymodestly
affected the number of CLP and moderately reduced
T cell development. T cell–speciﬁc deletion of Rac1
did not affect T-cell development, whereas deletion of
both Rac1 and Rac2 reduced immature CD4+CD8+
and mature CD4+ populations in thymus as well as
CD4+ and CD8+ populations in spleen.
Rac-deﬁcient mice also show abnormalities of the B
lineage, particularly in tissues requiring robust B cell
migration. InspiteofaperipheralbloodBcelllympho-
cytosis, Rac2−/−mice show reducednumbersof B1a
and marginal zone B cells and reduced IgM-secreting
plasma cells. Rac2−/− B cells demonstratea defect in
responses to combined stimulation of the B cell recep-
tor and CD19 [23]. Walmsley et al. [81] also report-
ed a severe block in B cell development in Rac1∆/∆;
Rac2−/− mice (where Rac1∆/∆ denotes the Rac1
genedeletionfromthe ﬂox allele). This blockwas par-
ticularly pronounced in the spleen and peritoneal cav-
ity. The B cells from the double knockout mice show
defective proliferation and survival associated with al-
terations in Akt and cyclin D activation. Furthermore,
these B cells fail to transduce B cell receptor signals
for upregulation of BAFF-R. This receptor for BAFF
is required for B cell development and maintenance.
7. Rac2 in mast cells studied in gene targeted mice
Mast cells can be derived in large numbers from
the bone marrow of mice after culture in vitro with
interleukin-3. Using this procedure, Rac2−/− mice
yield mast cells that have signiﬁcantly defective cell
growth and reduced survival [88]. These cells show
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activation, increased Bad expression, and reduced Bcl-
XL expression. Reduced activation of Akt is also con-
sistently foundin multiplebloodlineages of Rac2−/−
mice at least as assayed in vitro. Rac2-deﬁcient mast
cells also demonstrate reduced migration to stem cell
factor (SCF) and reduced mast cell degranulation to
IgE receptor cross-linking. Use of gene targeted mice
also demonstratedthat Rac2 plays a unique role in reg-
ulation of gene expression in mast cells [38]. In this
study cytokine-stimulated activation of MMCP-7 gene
transcription, a major granule protein, was selective-
ly regulated in mast cells by Rac2-dependent activa-
tion of JNK. Overall these studies show Rac2 plays an
important role in mast cell biology.
8. Rac2 in other blood cells studied in gene
targeted mice
There is much less known and published on the role
of Rac GTPases in other blood cells. Rac GTPas-
es are important in maintaining red blood cell mem-
braneintegrity[47]andappeartobecriticalforenucle-
ation [46]; Rac1∆/∆; Rac2−/− mice develop micro-
cyticanemiawithahemoglobindropofabout20%and
signiﬁcant anisocytosis and poikilocytosis associated
with reticulocytosis suggestive of a hemolytic process.
These changes are associated with abnormal actin and
spectrin cytoskeleton and reduced deformability. Fur-
thermore, deﬁciency of both Rac1 and Rac2 inhibits
theexpansionofveryearlyerythroidcellsinmice[48].
Rac2 is also important in platelet secretion and aggre-
gation[3]. Finally,abnormalactivationofRachasbeen
shown in a number of acute and chronic leukemias, in-
cluding chronic myelogenous leukemia, chronic lym-
phocytic leukemias and acute myeloid leukemias [59,
74,77,82]. Genetic or pharmacologicinhibition of Rac
leads to reduced proliferation and increased apoptosis
in some of these leukemias.
9. Rac3 knock-out mice
Rac3 is a third member of the Rac subfamily which
was originally identiﬁed from a chronic myelogenous
leukemia cell line and has been implicated in human
breast cancer [10,56], ovarian cancer [58], cellular
transformation [50] and tumor invasion [17]. Rac3 in-
teracts with the integrin binding protein, CIB, and pro-
motesintegrin-mediatedadhesionandspreadingin im-
mortalized cell lines. In addition, Rac3 is differential-
ly expressed during myeloid differentiation. Rac3 null
mutant mice [18,20] are viable, fertile and without ob-
vious physical anomalies, although one group has re-
portedamildneurologicalphenotype[12]. Inaddition,
inap190Bcr-abltransgenicmousemodelofacutelym-
phoblasticleukemia,Rac3, butnotRac1orRac2,is ac-
tivatedandRac3deﬁciencyattenuatesthedevelopment
of leukemia in mice, although for an unexplained rea-
son this attenuation was only seen in female mice [18].
In the absence of Rac1 and Rac2, Rac3 can mediate an
attenuated myelodysplastic phenotype in mice trans-
plantedwith p210Bcr-abl transducedHSC [77]. How-
ever, no systematic analysis of hematopoiesis has been
reported in Rac3−/− mice. Using RT-PCR and North-
ern blot analysis, Knaus and co-workers have report-
ed that the expression of Rac3 is dramatically down-
regulated during terminal myeloid differentiation, but
the functional signiﬁcance of this observation is un-
known [12]. We have demonstrated normal neutrophil
differentiationinRac1−/−;Rac2−/−cells[28,39],but
observed abnormal myeloid development in vitro after
transductionofHSC/PwiththeDND57NRac2mutant,
whichmostlikelyinhibitsRac3inadditiontoRac1and
Rac2[76]. Interestingly,HSC/PexpressingD57NRac2
failtoreconstitutehematopoiesiswhentransplantedin-
tolethallyirradiatedrecipients[38]. Thesedatasuggest
that Rac3 may be importantin myelopoiesis, but suffer
from the weaknesses of the use of DN mutants: the
effectsofcanbebothnon-speciﬁcandmaybedifferent
depending on the level of expression of the mutant in
the cell.
10. Rac2 dysfunction in humans, a complex
phenotype showing features of leukocyte
adhesion deﬁciency and chronic
granulomatous disease
As discussed above, cellular and whole animal stud-
ies have demonstrated that Rac2 has critical functions
in neutrophil adhesion, migration and killing. Rac2
has additionalroles in neutrophilfunctionand in T cell
development that are redundant with Rac1 and more
clearly deﬁned when Rac1 is absent. To date only one
case of RAC2 mutation in humans has been described
in detail [6,53,83]. The ﬁndings from this case have
now been corroborated by a second case, which came
to attention in the course of universal newborn screen-
inginWisconsinforseverecombinedimmunodeﬁcien-
cy (SCID) [69] and unpublished data (courtesy of J.
Routes, J. Verbsky et. al.). Below we describe howS.-Y. Pai et al. / Rac GTPases in human diseases 183
these two cases in many ways recapitulate the mouse
data, and in other ways demonstrate features of Rac2
function unique to humans.
Theclinicalpresentationofbothpatientswascharac-
terizedbydefectsinneutrophiladhesionandmigration.
Thepatientscametomedicalattentionasnewbornsdue
to infection around the umbilical stump. They were
notedtohaveneutrophiliaandleukocytosis,andunder-
went surgical debridement of umbilical area wounds.
The ﬁrst child had an infectedurachal cyst and also de-
veloped severe and recurrent perirectal abscesses that
grew Escherichia coli and Enterococcus. The second
child had omphalitis and a paratracheal abscess that
grew Stenotrophomonas and Prevotella. Both patients
had a dramatic absence of pus; however, biopsies re-
vealed detectable neutrophils, with acute inﬂammato-
ry inﬁltrate in the ﬁrst case and but minimal inﬁltrate
in the second. Leukocyte adhesion deﬁciency type I
(LAD type I, due to defects in ITGB2) (J. Routes and
J. Verbskymanuscriptin preparation)was initially sus-
pected but ruled out on the basis of normal expression
of the CD11b/CD18 complex by ﬂow cytometry [6,
53,83]. Treatment consisted of aggressive antibiotics,
granulocytetransfusions,andultimatelyhematopoietic
stem cell transplantation.
Investigators noted the striking similarity between
the ﬁrst child and what was at that time the recently
published Rac2−/− mouse [68]. Indeed, examination
of patient cells recapitulated the major ﬁndings seen in
the Rac2−/− mouse, including neutrophilia, defects
in chemotaxis, migration, F-actin formation, and se-
lective defects in NADPH oxidase activity, which is a
feature of chronic granulomatous disease (CGD) (Ta-
ble 1). Many of these ﬁndings were also seen in the
second patient. As noted above, the defect in NADPH
oxidase activity conﬁrms a long known requirement
for Rac GTPase activity in the generation of the ox-
idase in cell free systems [2,52], although no patient
hadbeendescribedintheCGD literaturewithadisease
attributable at the molecular level to mutation of any
Rac gene.
Both children were found to have a c.169G>A mu-
tation that results in a predicted protein change of
p.Asp57Asn (D57N). This mutation corresponds to
mutations in the GTP binding pocket of other Rho GT-
Pases and Ras superfamily members, such as p21Ras
D57A, that result in dominant negative activity. Thus
some of the clinical effects of this mutationare due not
only to lack of Rac2, but also due to inhibition of Rac1
activity [40], which in the mouse can compensate for
deletion of the Rac2 gene.
The second case points out additional interesting
functions of Rac GTPases in human hematopoiesis.
This patient had a mild defect in T cell development,
which was identiﬁed by universal newborn screening
for SCID [19,69]. SCID is a heterogeneous group
of congenital disorders of lymphocyte development
caused by at least 15 different genetic mutations. The
aim of this screening is to detect extreme T cell lym-
phopenia, the hallmark of SCID, by measuring T cell
receptor excision circles (TREC), an episomal circle
of DNA generated after T cell receptor alpha gene re-
arrangement in the late stages of thymocyte develop-
ment [25,62]. This child had complete absence of
TREC (0-4/microliter, mean value reported for nor-
mal newborns 225/microliter, cutoff for screening <
25/microliter). In contrast to patients with a classi-
cal SCID phenotype who lack T cells, the child had
a milder T cell lymphopenia (1434/microliter) and a
mild increase in the proportion of previously activat-
ed or memory phenotype cells, as indicated by expres-
sionofCD45RO[69].Thislatterﬁndingmayreﬂectthe
tendency of T cells under lymphopenic conditions to
undergoso-calledhomeostaticproliferation,andthere-
by gain expression of CD45RO. Low TREC typically
results from the additive effects of decreased thymic
output, resulting in low numbers of newly generated
TREC-containingna¨ ıveTcells,compoundedbyhome-
ostatic proliferation, which dilutes out the TREC as
T cells divide. Why the TREC are disproportionately
low in this case of mild lymphopenia remains unclear.
Overall the lymphocytephenotypeof the human muta-
tion is less severe than that seen in the doubly deﬁcient
mouse, which may reﬂect the differences between a
nullanda dominantnegativemutant. Infacttransgenic
expression of a different Rac dominant negative mu-
tant, Rac1N17 under control of the CD2 promoter, is
only mildly T cell lymphopenic [71].
Insummary,twoseparatecasesofRacdeﬁciencydue
to the presence of dominant negative mutations of the
Rac2 gene have now been described. The predominant
phenotype of the disease is leukocytosis with a failure
of neutrophil migration into infected tissues. Both in-
fants suffered from repeated life-threatening bacterial
infections,whoseseveritynecessitated allogeneicstem
cell transplantation. In both cases, the affected infants
weresuspectedofsufferingfromLAD.While thereare
more subtle aspects to the phenotypes, we propose the
term LAD type IV for this disease, as it most clearly
resembles other forms of LAD.184 S.-Y. Pai et al. / Rac GTPases in human diseases
11. Concluding remarks
Rho GTPases regulate a large number of cellular
functions, including cytoskeletal rearrangements that
control cell shape, adhesion and migration. Rac GT-
Pases have been implicated in cell migration, lamel-
lipodia formation and membrane rufﬂing in a variety
of mammalian cells, including some blood cells. The
developmentofgene-targetedmice deﬁcientin Rac2, a
hematopoietic-speciﬁcGTPase,identiﬁedaphagocytic
immunodeﬁciencyinthesemicethatconﬁrmedtheim-
portant and non-redundant role of this GTPase in sev-
eral blood cell lineages, particularly neutrophils. The
description of the murine Rac2−/− phenotype aided
in the identiﬁcation of a mutation in a patient with re-
currentseriousinfectionsininfancyandasimilarblood
phenotype. Subsequently, a second patient has been
identiﬁed with a similar phenotypeand identical muta-
tion. The phenotype of these patients, which includes
leukocytosis, reduced neutrophil chemotaxis and L-
selectin mediated endothelial rolling, most closely re-
sembles human LAD and we propose the syndrome be
named LAD type IV.
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